photo-1783961164464.jpg

Provide 10 drug interactions for this form in the format

Here are 10 drug interactions filled out in the format of the Pharmacist Intervention Reporting & Documentation Form from Farooqia College of Pharmacy:

PHARMACIST INTERVENTION REPORTING & DOCUMENTATION FORM

Case 1

Field	Details
Patient name	Mr. Ramesh Kumar
IP/OP No	IP/001
Reason for admission/visit C/O	Hypertension, Atrial Fibrillation
Drug related problem(s) identified	Warfarin + Aspirin - Concurrent use increases bleeding risk significantly (pharmacodynamic interaction)
Reason(s) for intervention	Patient prescribed both drugs simultaneously without gastroprotective cover; INR elevated
Suggestions made	Monitor INR closely; consider adding a proton pump inhibitor; evaluate necessity of dual therapy; reduce aspirin dose if essential
Informed to HCP?	Yes
Accepted?	Yes

Case 2

Field	Details
Patient name	Mrs. Sunita Devi
IP/OP No	IP/002
Reason for admission/visit C/O	Type 2 Diabetes, Bacterial Infection
Drug related problem(s) identified	Ciprofloxacin + Metformin - Ciprofloxacin can inhibit renal tubular secretion of metformin, increasing plasma levels and risk of lactic acidosis
Reason(s) for intervention	Patient on stable metformin dose; new ciprofloxacin prescription noted without dose adjustment
Suggestions made	Monitor blood glucose and renal function; consider temporary dose reduction of metformin; counsel patient on signs of lactic acidosis
Informed to HCP?	Yes
Accepted?	Yes

Case 3

Field	Details
Patient name	Mr. Ajay Sharma
IP/OP No	OP/003
Reason for admission/visit C/O	Epilepsy, Hypertension
Drug related problem(s) identified	Phenytoin + Amlodipine - Phenytoin induces CYP3A4, reducing plasma levels of amlodipine, leading to loss of antihypertensive control
Reason(s) for intervention	BP poorly controlled despite adequate amlodipine dose; interaction identified as likely cause
Suggestions made	Consider switching to a non-CYP3A4-metabolized antihypertensive (e.g., atenolol); increase amlodipine monitoring or increase dose with caution
Informed to HCP?	Yes
Accepted?	Yes

Case 4

Field	Details
Patient name	Mrs. Fatima Begum
IP/OP No	IP/004
Reason for admission/visit C/O	Depression, Migraine
Drug related problem(s) identified	SSRIs (Fluoxetine) + Sumatriptan - Risk of Serotonin Syndrome due to combined serotonergic activity
Reason(s) for intervention	Patient newly prescribed sumatriptan while on long-term fluoxetine; prescriber unaware of interaction
Suggestions made	Avoid combination if possible; if essential, counsel patient on symptoms of serotonin syndrome (hyperthermia, agitation, tremor, clonus); use lowest effective dose of sumatriptan
Informed to HCP?	Yes
Accepted?	Yes

Case 5

Field	Details
Patient name	Mr. Venkatesh Rao
IP/OP No	IP/005
Reason for admission/visit C/O	Chronic Kidney Disease, Gout
Drug related problem(s) identified	ACE Inhibitor (Enalapril) + NSAIDs (Indomethacin) - NSAIDs reduce prostaglandin-mediated renal afferent dilation, blunting ACE inhibitor efficacy and worsening renal function
Reason(s) for intervention	Serum creatinine rising; patient on both drugs for CKD-related hypertension and gout flare
Suggestions made	Discontinue NSAID; manage gout with colchicine or corticosteroids instead; monitor eGFR and potassium levels
Informed to HCP?	Yes
Accepted?	Yes

Case 6

Field	Details
Patient name	Ms. Priya Nair
IP/OP No	OP/006
Reason for admission/visit C/O	Tuberculosis, Oral Contraceptive Use
Drug related problem(s) identified	Rifampicin + Oral Contraceptive Pills (OCP) - Rifampicin strongly induces CYP3A4, reducing plasma estrogen/progesterone levels, leading to contraceptive failure
Reason(s) for intervention	Patient started on anti-TB regimen including rifampicin while continuing OCP without counseling
Suggestions made	Advise use of barrier contraception throughout TB treatment and for 1 month after stopping rifampicin; consider alternative non-hormonal contraception
Informed to HCP?	Yes
Accepted?	Yes

Case 7

Field	Details
Patient name	Mr. Suresh Patel
IP/OP No	IP/007
Reason for admission/visit C/O	Heart Failure, Gout
Drug related problem(s) identified	Digoxin + Allopurinol (via Furosemide-induced hypokalemia) - Furosemide causes potassium depletion, which sensitizes the myocardium to digoxin toxicity
Reason(s) for intervention	Patient on digoxin + furosemide; serum potassium 2.9 mEq/L; complaints of nausea and visual disturbances suggestive of digoxin toxicity
Suggestions made	Electrolyte replacement (IV/oral potassium); reduce digoxin dose; add potassium-sparing diuretic (spironolactone); check digoxin plasma levels
Informed to HCP?	Yes
Accepted?	Yes

Case 8

Field	Details
Patient name	Mrs. Rekha Iyer
IP/OP No	OP/008
Reason for admission/visit C/O	Hypothyroidism, Iron Deficiency Anemia
Drug related problem(s) identified	Levothyroxine + Ferrous Sulfate - Iron chelates levothyroxine in the GI tract, reducing its absorption by up to 30-40%
Reason(s) for intervention	Patient taking both medications simultaneously in the morning; TSH levels persistently elevated despite adequate levothyroxine dose
Suggestions made	Administer levothyroxine 30-60 minutes before breakfast; separate ferrous sulfate by at least 4 hours; recheck TSH after 6 weeks
Informed to HCP?	Yes
Accepted?	Yes

Case 9

Field	Details
Patient name	Mr. Mohammed Ali
IP/OP No	IP/009
Reason for admission/visit C/O	COPD, Anxiety Disorder
Drug related problem(s) identified	Theophylline + Benzodiazepine (Diazepam) - Benzodiazepines cause respiratory depression, which is dangerous in COPD patients already on theophylline for bronchodilation
Reason(s) for intervention	Patient prescribed diazepam for anxiety by psychiatry team; pulmonology team not informed; respiratory compromise risk identified
Suggestions made	Avoid benzodiazepines in COPD; consider buspirone for anxiety management; ensure interdepartmental communication; monitor SpO2 closely if benzodiazepine is unavoidable
Informed to HCP?	Yes
Accepted?	Yes

Case 10

Field	Details
Patient name	Mrs. Lakshmi Bai
IP/OP No	IP/010
Reason for admission/visit C/O	Osteoporosis, Hypertension
Drug related problem(s) identified	Bisphosphonate (Alendronate) + Calcium Supplements - Calcium significantly reduces oral absorption of alendronate when taken simultaneously
Reason(s) for intervention	Patient instructed to take alendronate with calcium tablet in the morning; bone density not improving as expected
Suggestions made	Alendronate must be taken on an empty stomach with plain water (not calcium, not food) 30 minutes before any food/supplement; take calcium at a separate time (e.g., with dinner)
Informed to HCP?	Yes
Accepted?	Yes

Summary of 10 Drug Interactions Documented:

#	Drug Pair	Mechanism	Clinical Risk
1	Warfarin + Aspirin	Pharmacodynamic (additive anticoagulation)	Bleeding
2	Ciprofloxacin + Metformin	Renal tubular secretion inhibition	Lactic acidosis
3	Phenytoin + Amlodipine	CYP3A4 induction	Loss of BP control
4	Fluoxetine + Sumatriptan	Serotonin excess	Serotonin syndrome
5	ACE Inhibitor + NSAIDs	Renal prostaglandin inhibition	Acute kidney injury
6	Rifampicin + OCP	CYP3A4 induction	Contraceptive failure
7	Digoxin + Furosemide	Hypokalemia sensitization	Digoxin toxicity
8	Levothyroxine + Ferrous Sulfate	Chelation (reduced absorption)	Hypothyroidism relapse
9	Theophylline + Diazepam	CNS/respiratory depression	Respiratory failure
10	Alendronate + Calcium	Absorption interference	Reduced drug efficacy

Provide 10 drug interactions for this form in the format In detail

Here are 10 detailed drug interactions documented in the Pharmacist Intervention Reporting & Documentation Form format from Farooqia College of Pharmacy, Department of Clinical Pharmacy:

FAROOQIA COLLEGE OF PHARMACY

Department of Clinical Pharmacy

PHARMACIST INTERVENTION REPORTING & DOCUMENTATION FORM

📋 CASE 1


Patient Name: Ramesh Kumar	Age: 62 yrs
IP/OP No: IP/2026/001	Weight (Kg): 72 kg
Date of Admission: 13/07/2026	Gender: Male
Intervention Date: 13/07/2026	Unit: Cardiology Ward

Reason for Admission/Visit C/O: Patient admitted with complaints of chest pain, palpitations, and shortness of breath. Diagnosed with Atrial Fibrillation (AF) and Ischemic Heart Disease. Currently on long-term anticoagulation therapy.

Drug Related Problem(s) Identified: Warfarin + Aspirin (300 mg) Both drugs were prescribed concurrently. Warfarin is a Vitamin K antagonist anticoagulant, and Aspirin irreversibly inhibits platelet COX-1, inhibiting thromboxane A2-mediated platelet aggregation. Together, they produce an additive/synergistic pharmacodynamic interaction increasing risk of serious and potentially life-threatening bleeding. Additionally, aspirin irritates the gastric mucosa, further compounding the hemorrhagic risk. INR on admission was found to be 4.2 (therapeutic range: 2.0-3.0). Patient reported black tarry stools (melena) - indicative of upper GI bleed.

Reason(s) for Intervention:

INR supratherapeutic at 4.2
Concurrent antiplatelet + anticoagulant therapy without gastroprotective cover
Melena suggesting active GI bleeding
No prior documentation of this combination being intentional (e.g., mechanical heart valve indication)
Patient had not been counseled about bleeding risk signs

Suggestions Made:

Temporarily hold warfarin dose and recheck INR after 48 hours
Add Pantoprazole 40 mg OD as gastroprotective therapy
Evaluate whether dual therapy (warfarin + aspirin) is truly necessary for this patient's indication
If dual therapy is essential (e.g., AF + recent ACS), reduce aspirin to lowest effective dose (75 mg)
Counsel patient on signs of bleeding: unusual bruising, blood in urine, black stools
Dietary counseling on Vitamin K-containing foods
Regular INR monitoring every 2 weeks

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Suresh Naik, Cardiologist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 2


Patient Name: Sunita Devi	Age: 55 yrs
IP/OP No: IP/2026/002	Weight (Kg): 65 kg
Date of Admission: 13/07/2026	Gender: Female
Intervention Date: 13/07/2026	Unit: General Medicine

Reason for Admission/Visit C/O: Patient with known Type 2 Diabetes Mellitus (on Metformin 1000 mg BD) admitted with urinary tract infection (UTI). Ciprofloxacin 500 mg BD prescribed by treating physician.

Drug Related Problem(s) Identified: Ciprofloxacin + Metformin Ciprofloxacin, a fluoroquinolone antibiotic, inhibits organic cation transporter 2 (OCT2) in the renal tubules, which is the primary secretory pathway for metformin elimination. This inhibition leads to reduced renal clearance of metformin, resulting in increased plasma metformin concentrations. Elevated metformin levels predispose the patient to lactic acidosis - a rare but potentially fatal complication. Furthermore, fluoroquinolones can independently cause dysglycemia (both hypoglycemia and hyperglycemia), complicating diabetic management. Blood glucose on the day of admission was 58 mg/dL (hypoglycemia episode noted).

Reason(s) for Intervention:

Hypoglycemia episode on Day 1 of combined therapy
Metformin dose not adjusted despite new fluoroquinolone prescription
Patient's eGFR borderline at 52 mL/min/1.73m² (reduced renal clearance of metformin already compromised)
No monitoring plan documented for renal function or blood glucose during antibiotic course

Suggestions Made:

Reduce Metformin dose to 500 mg BD during the antibiotic course
Closely monitor blood glucose 4-hourly
Monitor serum creatinine and eGFR every 48 hours
Consider switching antibiotic to Nitrofurantoin or Co-trimoxazole for uncomplicated UTI (less interaction risk)
Counsel patient to immediately report symptoms of lactic acidosis: muscle pain, weakness, difficulty breathing, stomach discomfort
Resume standard metformin dose only after completing the antibiotic course and confirming stable renal function

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Meera Krishnamurthy, Physician
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 3


Patient Name: Ajay Sharma	Age: 48 yrs
IP/OP No: OP/2026/003	Weight (Kg): 80 kg
Date of Admission: 13/07/2026	Gender: Male
Intervention Date: 13/07/2026	Unit: Neurology OPD

Reason for Admission/Visit C/O: Patient with longstanding epilepsy (on Phenytoin 300 mg OD) presenting for review. Also diagnosed with essential hypertension 3 months ago; Amlodipine 10 mg OD prescribed. BP poorly controlled (156/98 mmHg today) despite 3 months of Amlodipine at maximum dose.

Drug Related Problem(s) Identified: Phenytoin + Amlodipine Phenytoin is a potent inducer of the hepatic cytochrome P450 enzyme CYP3A4. Amlodipine, a dihydropyridine calcium channel blocker, is primarily metabolized by CYP3A4. When phenytoin induces CYP3A4, the rate of amlodipine metabolism is significantly accelerated, reducing amlodipine plasma concentrations by up to 80-90% in some studies. This results in subtherapeutic levels of amlodipine and a consequent loss of antihypertensive effect, explaining the persistent poor BP control in this patient despite maximum dosing.

Reason(s) for Intervention:

BP inadequately controlled at 156/98 mmHg on maximum dose amlodipine (10 mg OD)
Drug interaction with phenytoin (CYP3A4 inducer) identified as the pharmacokinetic cause
Further increasing amlodipine dose beyond 10 mg is not recommended and would be ineffective
Risk of hypertensive complications (stroke, MI) if left unaddressed

Suggestions Made:

Discontinue Amlodipine - futile in presence of strong CYP3A4 inducer
Switch to Atenolol 50 mg OD (beta-blocker, not CYP3A4 substrate - safe alternative)
Alternatively, consider Losartan (ARB) - minimal CYP3A4 involvement
If BP control is still inadequate, Chlorthalidone (thiazide-like diuretic) may be added
Recheck BP in 4 weeks after switching antihypertensive
Therapeutic drug monitoring (TDM) of phenytoin levels to ensure anti-epileptic efficacy is maintained
Do not abruptly stop phenytoin - risk of breakthrough seizures

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Praveen Kamath, Neurologist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 4


Patient Name: Fatima Begum	Age: 60 yrs
IP/OP No: IP/2026/004	Weight (Kg): 58 kg
Date of Admission: 13/07/2026	Gender: Female
Intervention Date: 13/07/2026	Unit: Psychiatry

Reason for Admission/Visit C/O: Patient with chronic Major Depressive Disorder (MDD) on Fluoxetine 40 mg OD for 18 months. Referred to neurology for newly diagnosed migraine attacks; Sumatriptan 50 mg PRN prescribed for acute migraine episodes.

Drug Related Problem(s) Identified: Fluoxetine (SSRI) + Sumatriptan (Triptan) Fluoxetine enhances serotonergic neurotransmission by blocking the serotonin reuptake transporter (SERT), increasing synaptic serotonin levels. Sumatriptan is a selective 5-HT1B/1D receptor agonist acting on serotonin receptors to constrict intracranial blood vessels. When used concurrently, the combined serotonergic activity - presynaptic serotonin accumulation (from SSRI) plus direct receptor agonism (from triptan) - can precipitate Serotonin Syndrome. This life-threatening condition manifests as a triad of: (1) altered mental status/agitation, (2) autonomic instability (tachycardia, hyperthermia, diaphoresis), and (3) neuromuscular abnormalities (tremor, hyperreflexia, clonus, myoclonus). Patient reported palpitations and mild restlessness after first sumatriptan dose.

Reason(s) for Intervention:

High-risk serotonin syndrome combination prescribed without interdepartmental communication
Patient already experienced mild symptoms (palpitations, restlessness) after first use
Both prescribers unaware of each other's prescriptions
60-year-old female patient - higher vulnerability to adverse drug reactions

Suggestions Made:

Discontinue Sumatriptan immediately
If migraine treatment is essential, consider switching to NSAIDs (Naproxen), antiemetics (Metoclopramide), or Paracetamol for acute attacks
If triptan therapy is unavoidable, consider low-dose Naratriptan or Frovatriptan with close monitoring - these have less serotonergic affinity
Educate patient on warning symptoms of serotonin syndrome: fever, agitation, shivering, diarrhea, muscle twitching
Implement medication reconciliation across psychiatry and neurology departments
Consider non-pharmacological migraine management (trigger avoidance, relaxation techniques)

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Anand Reddy, Psychiatrist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 5


Patient Name: Venkatesh Rao	Age: 70 yrs
IP/OP No: IP/2026/005	Weight (Kg): 75 kg
Date of Admission: 13/07/2026	Gender: Male
Intervention Date: 13/07/2026	Unit: Nephrology

Reason for Admission/Visit C/O: Chronic Kidney Disease Stage 3 (CKD-3) with hypertension managed on Enalapril 10 mg OD. Admitted with acute gout flare; Indomethacin 50 mg TDS prescribed for 5 days.

Drug Related Problem(s) Identified: ACE Inhibitor (Enalapril) + NSAID (Indomethacin) This is a well-documented and clinically serious triple whammy interaction (especially dangerous in CKD). The mechanism is multifactorial:

NSAIDs inhibit prostaglandin (PGE2 and PGI2) synthesis in the kidney. These prostaglandins normally dilate the afferent arteriole to maintain glomerular filtration pressure. When prostaglandins are inhibited, afferent arteriolar constriction occurs, reducing GFR.
ACE inhibitors simultaneously block angiotensin II-mediated efferent arteriolar constriction, which ordinarily compensates for reduced afferent flow.
Together, both drugs unmask a state of hemodynamic renal vulnerability leading to Acute Kidney Injury (AKI) superimposed on CKD. Serum creatinine rose from baseline 1.6 mg/dL to 2.4 mg/dL within 48 hours of adding indomethacin.

Reason(s) for Intervention:

Rapidly rising creatinine (1.6 to 2.4 mg/dL in 48 hrs)
Urine output decreased to 600 mL/day
Patient already has CKD-3 - vulnerable baseline renal function
NSAIDs are contraindicated or strongly cautioned in CKD + ACE inhibitor combination

Suggestions Made:

Immediately discontinue Indomethacin
Manage acute gout with Colchicine 0.5 mg BD (renal-dose adjusted) as first alternative
If colchicine is not tolerated, use short-course oral Prednisolone 20-30 mg OD
Ensure adequate hydration (IV fluids if oral intake inadequate)
Monitor serum creatinine, urea, and electrolytes daily until renal function stabilizes
Monitor potassium closely - ACE inhibitor + renal impairment can cause dangerous hyperkalemia
Continue Enalapril but reduce dose if eGFR falls below 30 mL/min/1.73m²

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Rajesh Shetty, Nephrologist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 6


Patient Name: Priya Nair	Age: 35 yrs
IP/OP No: OP/2026/006	Weight (Kg): 54 kg
Date of Admission: 13/07/2026	Gender: Female
Intervention Date: 13/07/2026	Unit: OB-GYN / Pulmonology

Reason for Admission/Visit C/O: Young female patient on Combined Oral Contraceptive Pill (COCP - Ethinylestradiol + Levonorgestrel) for contraception. Newly diagnosed with Pulmonary Tuberculosis (PTB); initiated on RIPE regimen (Rifampicin 600 mg OD, Isoniazid, Pyrazinamide, Ethambutol).

Drug Related Problem(s) Identified: Rifampicin + Combined Oral Contraceptive Pill (Ethinylestradiol + Levonorgestrel) Rifampicin is one of the most potent inducers of hepatic CYP3A4, CYP2C9, and P-glycoprotein (P-gp). Ethinylestradiol and progestogens (levonorgestrel) in OCPs are primarily metabolized by CYP3A4. Rifampicin dramatically accelerates their hepatic metabolism, reducing plasma levels of both estrogen and progestogen by 40-80%. This renders hormonal contraception clinically ineffective, with a very high risk of unintended pregnancy during the TB treatment period (minimum 6 months). Additionally, rifampicin enhances gut P-gp activity, further reducing OCP absorption. The enzyme induction persists for 4-8 weeks after stopping rifampicin.

Reason(s) for Intervention:

Patient not counseled about contraceptive failure risk when started on RIPE regimen
Unintended pregnancy during anti-TB treatment poses serious fetal risks (drug teratogenicity - Pyrazinamide, Ethambutol safety profiles in pregnancy)
Patient's reproductive planning entirely dependent on a now-ineffective method

Suggestions Made:

Counsel patient clearly that the OCP is NO LONGER EFFECTIVE as contraception during rifampicin treatment
Immediately switch to a barrier method (condoms) or copper intrauterine device (Cu-IUD) as highly effective non-hormonal alternatives
Continue OCP only if patient insists, but must use dual contraception (OCP + barrier)
Maintain non-hormonal contraception for at least 4-8 weeks after completing rifampicin
Document counseling provided and patient's informed consent
Coordinate with OB-GYN for IUD insertion if opted
Do NOT use high-dose OCP as a solution - insufficient to overcome enzyme induction

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Kavitha Bhat, Pulmonologist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 7


Patient Name: Suresh Patel	Age: 65 yrs
IP/OP No: IP/2026/007	Weight (Kg): 82 kg
Date of Admission: 13/07/2026	Gender: Male
Intervention Date: 13/07/2026	Unit: Cardiology

Reason for Admission/Visit C/O: Chronic Heart Failure (CHF - NYHA Class III) on Digoxin 0.25 mg OD and Furosemide 80 mg OD. Patient presents with complaints of nausea, vomiting, yellow-green visual halos, and bradycardia (HR: 46 bpm). Serum potassium: 2.8 mEq/L (normal: 3.5-5.0). Digoxin level: 3.2 ng/mL (therapeutic: 0.5-2.0 ng/mL).

Drug Related Problem(s) Identified: Digoxin + Furosemide (via Furosemide-induced Hypokalemia) This is an indirect but life-threatening pharmacodynamic interaction. Furosemide, a loop diuretic, causes renal potassium wasting through its action on the Na-K-2Cl cotransporter in the thick ascending limb of the Loop of Henle. The resulting hypokalemia (K⁺ 2.8 mEq/L) dramatically potentiates digoxin toxicity through a shared mechanism: Digoxin inhibits Na⁺/K⁺-ATPase on cardiac myocytes. Hypokalemia also inhibits Na⁺/K⁺-ATPase (since K⁺ is the natural activator substrate), creating a synergistic inhibitory effect. This results in markedly elevated intracellular calcium via the Na⁺/Ca²⁺ exchanger, producing dangerous ventricular arrhythmias, bradycardia, and the classic signs of digoxin toxicity seen in this patient.

Reason(s) for Intervention:

Digoxin toxicity confirmed: level 3.2 ng/mL (supratherapeutic) + clinical symptoms (nausea, visual disturbances, bradycardia)
Furosemide-induced hypokalemia (K⁺ 2.8 mEq/L) exacerbating toxicity
Patient not on potassium supplementation despite long-term furosemide use
Bradycardia (HR 46 bpm) indicating risk of complete heart block

Suggestions Made:

URGENT: Hold Digoxin immediately
Administer IV Potassium Chloride (KCl) infusion - 40 mEq in 500 mL NS over 4 hours under continuous ECG monitoring
Attach cardiac monitor continuously; watch for AV block, VT, VF
If digoxin toxicity severe with life-threatening arrhythmia, consider Digoxin-specific Fab antibody fragments (Digibind/DigiFab)
Add Spironolactone 25 mg OD (potassium-sparing diuretic) to ongoing furosemide to prevent recurrent hypokalemia
Reduce Furosemide dose to minimum effective dose for symptom control
Once stable, restart Digoxin at reduced dose (0.125 mg OD) with strict TDM
Dietary counseling: increase potassium-rich foods (bananas, oranges, potatoes) within cardiac diet restrictions

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Suresh Naik, Cardiologist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 8


Patient Name: Rekha Iyer	Age: 45 yrs
IP/OP No: OP/2026/008	Weight (Kg): 61 kg
Date of Admission: 13/07/2026	Gender: Female
Intervention Date: 13/07/2026	Unit: Endocrinology OPD

Reason for Admission/Visit C/O: Patient with primary hypothyroidism on Levothyroxine 150 mcg OD presents for review. TSH persistently elevated at 8.4 mIU/L (normal: 0.4-4.0) despite 6 months of therapy and two dose increments. Concurrent history of iron-deficiency anemia, prescribed Ferrous Sulfate 200 mg TDS.

Drug Related Problem(s) Identified: Levothyroxine + Ferrous Sulfate Ferrous sulfate (Fe²⁺) forms an insoluble chelate complex with levothyroxine in the gastrointestinal tract when taken simultaneously. This physicochemical interaction (chelation) significantly impairs the intestinal absorption of levothyroxine, reducing its bioavailability by 30-50% (some studies report up to 80% reduction in AUC). The reduced absorption leads to persistently subtherapeutic levothyroxine plasma levels, explaining the inadequate TSH suppression in this patient. Similar interactions occur with other divalent cations: calcium carbonate, antacids (Al³⁺, Mg²⁺), and sucralfate. Patient was taking both tablets simultaneously every morning as instructed on packaging, without being counseled about the spacing requirement.

Reason(s) for Intervention:

Persistently elevated TSH (8.4 mIU/L) despite adequate levothyroxine dose and two prior dose increments
Patient unnecessarily received higher doses of levothyroxine because the root cause (interaction) was not identified
Drug interaction not documented by any prior prescriber despite concurrent prescription for 6 months
Patient symptomatic: fatigue, cold intolerance, weight gain - indicative of uncontrolled hypothyroidism

Suggestions Made:

Instruct patient to take Levothyroxine FIRST, 30-60 minutes before breakfast, on an EMPTY stomach with plain water only
Take Ferrous Sulfate at a SEPARATE time - minimum 4 hours after levothyroxine (ideally with lunch or dinner)
Do NOT co-administer with calcium supplements, antacids, or dairy products
Reassess the previously increased levothyroxine dose - may now be excessive once absorption normalizes
Recheck TSH and Free T4 levels in 6 weeks after correcting the timing
Titrate levothyroxine dose downward if needed once interaction is resolved
Educate patient clearly on the critical importance of timing - compliance is the cornerstone of therapy

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Girish Rao, Endocrinologist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 9


Patient Name: Mohammed Irfan	Age: 52 yrs
IP/OP No: IP/2026/009	Weight (Kg)
Date of Admission: 13/07/2026	Gender: Male
Intervention Date: 13/07/2026	Unit: Pulmonology

Reason for Admission/Visit C/O: COPD (GOLD Stage III, moderate-severe) on Theophylline SR 400 mg BD for bronchodilation. Patient recently started on Clarithromycin 500 mg BD by a general practitioner for community-acquired pneumonia. Now presenting with nausea, vomiting, tachycardia (HR: 122 bpm), and tremors.

Drug Related Problem(s) Identified: Theophylline + Clarithromycin Theophylline has a very narrow therapeutic index (NTI); therapeutic range: 10-20 mcg/mL; toxic range: >20 mcg/mL. It is primarily metabolized by hepatic CYP1A2 and CYP3A4. Clarithromycin, a macrolide antibiotic, is a potent inhibitor of CYP3A4 (and to a lesser extent CYP1A2). When clarithromycin inhibits these enzymes, theophylline clearance is significantly reduced, leading to accumulation of theophylline to toxic levels. Theophylline toxicity is characterized by: GI symptoms (nausea, vomiting), cardiovascular effects (tachycardia, palpitations, arrhythmias), and neurological effects (tremors, seizures, agitation). Serum theophylline level on admission: 28 mcg/mL (toxic). Other CYP-inhibiting drugs with similar interaction: Erythromycin, Ciprofloxacin, Enoxacin, Cimetidine.

Reason(s) for Intervention:

Clinical theophylline toxicity confirmed: level 28 mcg/mL + tachycardia, tremors, vomiting
Clarithromycin prescribed by GP without checking patient's existing medication profile
Theophylline dose was not adjusted despite addition of a known CYP3A4 inhibitor
Narrow therapeutic index drug with serious toxicity consequences

Suggestions Made:

URGENT: Withhold Theophylline immediately; check serum theophylline level STAT
Discontinue Clarithromycin; substitute with Doxycycline 100 mg BD or Amoxicillin-Clavulanate (no significant theophylline interaction)
Symptomatic management: IV fluids for dehydration; beta-blockers (e.g., Propranolol) if tachycardia severe and no contraindication
Continuous cardiac monitoring (ECG) until theophylline level falls within therapeutic range
Once symptoms resolve and levels normalize, restart theophylline at 75% of previous dose
If clarithromycin cannot be substituted, reduce theophylline dose by 50% and monitor levels every 48 hours
Patient education: Never take new medications (including OTC) without informing the pharmacist/prescriber due to theophylline's narrow safety margin

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Kavitha Bhat, Pulmonologist
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

📋 CASE 10


Patient Name: Lakshmi Bai	Age: 68 yrs
IP/OP No: OP/2026/010	Weight (Kg): 63 kg
Date of Admission: 13/07/2026	Gender: Female
Intervention Date: 13/07/2026	Unit: Orthopedics OPD

Reason for Admission/Visit C/O: Post-menopausal woman with established osteoporosis. On Alendronate 70 mg once weekly and Calcium Carbonate 1250 mg + Vitamin D3 500 IU BD. Attending OPD for follow-up bone mineral density (BMD) review - DEXA scan shows worsening osteoporosis (T-score: -3.2) despite 18 months of therapy. Patient takes all medications together in the morning before breakfast.

Drug Related Problem(s) Identified: Alendronate (Bisphosphonate) + Calcium Carbonate Bisphosphonates have inherently poor oral bioavailability (approximately 1-5% under optimal conditions). This bioavailability drops dramatically when taken with calcium supplements, dairy products, food, or any polyvalent cation. The mechanism is a direct physicochemical interaction in the GI lumen: calcium ions (Ca²⁺) chelate with the bisphosphonate molecule, forming an insoluble calcium-alendronate complex that cannot be absorbed across the intestinal epithelium. Studies show co-administration reduces alendronate bioavailability by more than 60%. As a result, systemic levels of alendronate are insufficient to inhibit osteoclast activity, leading to continued bone resorption and worsening osteoporosis - exactly what is seen in this patient (worsening T-score despite 18 months of treatment). The prescribing instructions for alendronate explicitly require: take on empty stomach, with 200-250 mL plain water, at least 30-60 minutes before first food/drink/medication of the day.

Reason(s) for Intervention:

Worsening BMD (T-score -3.2) despite 18 months of alendronate - therapy appearing ineffective
Interaction identified as the cause of treatment failure: patient taking alendronate WITH calcium carbonate simultaneously
Continued bone loss increases fracture risk significantly in a 68-year-old female
No pharmacist counseling previously documented on correct alendronate administration technique

Suggestions Made:

Instruct patient on CORRECT administration: Alendronate 70 mg taken once weekly on an EMPTY STOMACH, upon waking, with a FULL glass (250 mL) of plain water ONLY
Patient must remain UPRIGHT (sitting/standing) for at least 30 minutes after taking alendronate (prevents esophageal ulceration)
Must NOT eat, drink (except plain water), or take any other medication for at least 30-60 minutes after alendronate
Take Calcium Carbonate + Vitamin D at a separate time - preferably with meals (lunch or dinner), at least 2 hours after alendronate
Recheck BMD in 12 months after correcting the administration technique - expect improvement
Assess other modifiable osteoporosis risk factors: smoking, alcohol, physical activity, falls prevention
Provide a written instruction card for correct alendronate administration and pin to medication packaging

Informed to HCP?	☑ Yes ☐ No
Accepted?	☑ Yes ☐ No
Name & Signature of HCP: Dr. Mahesh Shenoy, Orthopedic Surgeon
Name & Signature of Pharmacist: Pharm. Arjun Hegde
Preceptor's Name & Signature: Dr. Noorjahan, Dept. of Clinical Pharmacy

Summary Reference Table

Case	Drug Pair	Mechanism	Severity	Clinical Outcome	Key Action
1	Warfarin + Aspirin	Pharmacodynamic (additive anticoagulation + GI mucosal injury)	Major	GI Bleeding, supratherapeutic INR	Hold warfarin, add PPI, lowest aspirin dose
2	Ciprofloxacin + Metformin	OCT2 inhibition → reduced metformin renal clearance	Major	Lactic acidosis, hypoglycemia	Dose reduce metformin, alternate antibiotic
3	Phenytoin + Amlodipine	CYP3A4 induction → reduced amlodipine levels	Major	Uncontrolled hypertension	Switch to atenolol/losartan
4	Fluoxetine + Sumatriptan	Combined serotonergic activity	Major/Life-threatening	Serotonin Syndrome	Stop sumatriptan, use NSAIDs for migraine
5	Enalapril + Indomethacin	Dual renal haemodynamic compromise	Major	Acute Kidney Injury on CKD	Stop NSAID, use colchicine/steroids for gout
6	Rifampicin + OCP	CYP3A4 induction → reduced estrogen/progestogen levels	Major	Contraceptive failure	Switch to copper-IUD or barrier method
7	Digoxin + Furosemide	Hypokalemia potentiates Na/K-ATPase inhibition	Life-threatening	Digoxin toxicity, bradycardia, arrhythmias	Hold digoxin, IV potassium, add spironolactone
8	Levothyroxine + Ferrous Sulfate	Chelation → reduced levothyroxine absorption	Moderate-Major	Uncontrolled hypothyroidism	Separate by 4+ hours, empty stomach for T4
9	Theophylline + Clarithromycin	CYP3A4 inhibition → theophylline toxicity	Major/Life-threatening	Tachycardia, tremors, seizure risk	Hold theophylline, substitute antibiotic
10	Alendronate + Calcium Carbonate	Chelation in GI tract → reduced alendronate absorption	Moderate	Therapeutic failure, worsening osteoporosis	Correct timing, separate by 2+ hours

Create a Word document with these 10 drug interactions for training reference

Reading File

Running Command

mkdir -p /home/daytona/workspace/drug-interactions && ls /home/daytona/workspace…

Writing File

~/drug-interactions/generate.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, PageBreak, Header, Footer, LevelFormat
} = require('docx');
const fs = require('fs');

// ── Colour palette ──────────────────────────────────────────────────────────
const NAVY   = "1F3864";  // dark navy – headers
const TEAL   = "1F7A8C";  // teal – case title bars
const LIGHT  = "D9E8F0";  // light blue – shading
const YELLOW = "FFF2CC";  // light yellow – highlight rows
const WHITE  = "FFFFFF";
const BLACK  = "000000";
const RED    = "C00000";  // severity major/life-threatening
const GREEN  = "375623";  // accepted

// ── Helper: bold coloured text ───────────────────────────────────────────────
const run = (text, opts = {}) =>
  new TextRun({ text, font: "Arial", size: opts.size || 22,
    bold: opts.bold || false, italics: opts.italics || false,
    color: opts.color || BLACK, allCaps: opts.allCaps || false });

// ── Helper: paragraph ────────────────────────────────────────────────────────
const para = (children, opts = {}) =>
  new Paragraph({
    alignment: opts.align || AlignmentType.LEFT,
    spacing: { before: opts.before ?? 60, after: opts.after ?? 60 },
    children: Array.isArray(children) ? children : [children]
  });

// ── Helper: section heading paragraph ───────────────────────────────────────
const fieldLabel = (label, value) =>
  para([
    run(label + ": ", { bold: true, size: 20, color: NAVY }),
    run(value, { size: 20 })
  ], { before: 40, after: 40 });

// ── Helper: numbered suggestion ─────────────────────────────────────────────
const suggLine = (n, text) =>
  new Paragraph({
    spacing: { before: 30, after: 30 },
    indent: { left: 360, hanging: 280 },
    children: [
      run(n + ". ", { bold: true, size: 20, color: TEAL }),
      run(text, { size: 20 })
    ]
  });

// ── Helper: coloured cell ────────────────────────────────────────────────────
const cell = (text, opts = {}) =>
  new TableCell({
    shading: opts.shade ? { fill: opts.shade, type: ShadingType.CLEAR, color: "auto" } : undefined,
    width: opts.width ? { size: opts.width, type: WidthType.DXA } : undefined,
    columnSpan: opts.span || 1,
    verticalAlign: VerticalAlign.CENTER,
    margins: { top: 80, bottom: 80, left: 120, right: 120 },
    borders: opts.noBorder ? {
      top: { style: BorderStyle.NONE }, bottom: { style: BorderStyle.NONE },
      left: { style: BorderStyle.NONE }, right: { style: BorderStyle.NONE }
    } : undefined,
    children: [
      new Paragraph({
        alignment: opts.center ? AlignmentType.CENTER : AlignmentType.LEFT,
        spacing: { before: 0, after: 0 },
        children: [run(text, { bold: opts.bold || false, size: opts.size || 20,
          color: opts.color || BLACK, italics: opts.italics || false })]
      })
    ]
  });

// ── Helper: table row ────────────────────────────────────────────────────────
const trow = (cells) => new TableRow({ children: cells });

// ── Helper: page break ───────────────────────────────────────────────────────
const pageBreak = () => new Paragraph({ children: [new PageBreak()] });

// ── Helper: horizontal rule (thick border bottom) ───────────────────────────
const hrule = () => new Paragraph({
  spacing: { before: 0, after: 0 },
  border: { bottom: { style: BorderStyle.THICK, size: 6, color: TEAL } },
  children: [run("")]
});

// ── Case title bar ────────────────────────────────────────────────────────────
const caseTitle = (n, title) =>
  new Paragraph({
    spacing: { before: 160, after: 80 },
    shading: { fill: TEAL, type: ShadingType.CLEAR, color: "auto" },
    alignment: AlignmentType.CENTER,
    children: [
      run(`CASE ${n}  |  `, { bold: true, size: 26, color: WHITE }),
      run(title, { bold: true, size: 26, color: WHITE })
    ]
  });

// ── Section label paragraph ───────────────────────────────────────────────────
const sectionLabel = (text) =>
  new Paragraph({
    spacing: { before: 120, after: 40 },
    shading: { fill: LIGHT, type: ShadingType.CLEAR, color: "auto" },
    children: [run(text, { bold: true, size: 21, color: NAVY, allCaps: true })]
  });

// ── Patient info table ────────────────────────────────────────────────────────
const patientTable = (data) => new Table({
  width: { size: 9026, type: WidthType.DXA },
  rows: [
    trow([
      cell("Patient Name:", { shade: LIGHT, bold: true, size: 19, width: 1800 }),
      cell(data.name, { size: 19, width: 2000 }),
      cell("Age:", { shade: LIGHT, bold: true, size: 19, width: 800 }),
      cell(data.age, { size: 19, width: 800 }),
      cell("Date of Admission:", { shade: LIGHT, bold: true, size: 19, width: 1800 }),
      cell(data.doa, { size: 19, width: 1826 })
    ]),
    trow([
      cell("IP/OP No:", { shade: LIGHT, bold: true, size: 19 }),
      cell(data.ipop, { size: 19 }),
      cell("Wt (kg):", { shade: LIGHT, bold: true, size: 19 }),
      cell(data.weight, { size: 19 }),
      cell("Gender:", { shade: LIGHT, bold: true, size: 19 }),
      cell(data.gender, { size: 19 })
    ]),
    trow([
      cell("Intervention Date:", { shade: LIGHT, bold: true, size: 19 }),
      cell(data.intDate, { size: 19 }),
      cell("Unit:", { shade: LIGHT, bold: true, size: 19 }),
      cell(data.unit, { size: 19, span: 3 })
    ])
  ]
});

// ── Text block ────────────────────────────────────────────────────────────────
const textBlock = (text) =>
  new Paragraph({ spacing: { before: 40, after: 40 }, children: [run(text, { size: 20 })] });

// ── Signature table ────────────────────────────────────────────────────────────
const sigTable = (hcp, pharmacist, preceptor, informed, accepted) =>
  new Table({
    width: { size: 9026, type: WidthType.DXA },
    rows: [
      trow([
        cell("Informed to HCP?", { shade: LIGHT, bold: true, size: 19, width: 2000 }),
        cell(informed, { size: 20, bold: true, color: informed === "YES" ? GREEN : RED, width: 2513 }),
        cell("Name & Signature of HCP:", { shade: LIGHT, bold: true, size: 19, width: 2000 }),
        cell(hcp, { size: 19, width: 2513 })
      ]),
      trow([
        cell("Accepted?", { shade: LIGHT, bold: true, size: 19 }),
        cell(accepted, { size: 20, bold: true, color: accepted === "YES" ? GREEN : RED }),
        cell("Name & Signature of Pharmacist:", { shade: LIGHT, bold: true, size: 19 }),
        cell(pharmacist, { size: 19 })
      ]),
      trow([
        cell("Preceptor's Name & Signature:", { shade: LIGHT, bold: true, size: 19 }),
        cell(preceptor, { size: 19, span: 3 })
      ])
    ]
  });

// ═══════════════════════════════════════════════════════════════════════════════
// SUMMARY TABLE
// ═══════════════════════════════════════════════════════════════════════════════
const summaryTable = () => {
  const headers = ["#", "Drug Pair", "Mechanism", "Severity", "Clinical Risk", "Key Action"];
  const widths  = [400, 2000, 2000, 1000, 1600, 2026];
  const rows = [
    ["1","Warfarin + Aspirin","Additive anticoagulation + GI mucosal injury","MAJOR","GI Bleeding, supratherapeutic INR","Hold warfarin, add PPI"],
    ["2","Ciprofloxacin + Metformin","OCT2 inhibition -> reduced renal clearance","MAJOR","Lactic acidosis, hypoglycemia","Dose-reduce metformin; alternate antibiotic"],
    ["3","Phenytoin + Amlodipine","CYP3A4 induction -> subtherapeutic amlodipine","MAJOR","Uncontrolled hypertension","Switch to atenolol/losartan"],
    ["4","Fluoxetine + Sumatriptan","Combined serotonergic excess","LIFE-THREATENING","Serotonin Syndrome","Stop sumatriptan; use NSAIDs for migraine"],
    ["5","ACE Inhibitor + Indomethacin","Dual renal haemodynamic compromise","MAJOR","AKI on CKD","Stop NSAID; use colchicine/steroids"],
    ["6","Rifampicin + OCP","CYP3A4 induction -> reduced OCP levels","MAJOR","Contraceptive failure","Switch to copper-IUD or barrier method"],
    ["7","Digoxin + Furosemide","Hypokalemia potentiates Na/K-ATPase inhibition","LIFE-THREATENING","Digoxin toxicity, bradycardia","Hold digoxin; IV K+; add spironolactone"],
    ["8","Levothyroxine + Ferrous Sulfate","Chelation -> reduced T4 absorption","MODERATE","Uncontrolled hypothyroidism","Separate by 4+ hrs; empty stomach for T4"],
    ["9","Theophylline + Clarithromycin","CYP3A4 inhibition -> theophylline accumulation","LIFE-THREATENING","Toxicity: tachycardia, seizures","Hold theophylline; substitute antibiotic"],
    ["10","Alendronate + Calcium Carbonate","GI chelation -> reduced bisphosphonate absorption","MODERATE","Therapeutic failure, worsening osteoporosis","Correct timing; separate by 2+ hours"],
  ];

  const headerRow = trow(headers.map((h, i) =>
    new TableCell({
      shading: { fill: NAVY, type: ShadingType.CLEAR, color: "auto" },
      width: { size: widths[i], type: WidthType.DXA },
      verticalAlign: VerticalAlign.CENTER,
      margins: { top: 80, bottom: 80, left: 100, right: 100 },
      children: [new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 0, after: 0 },
        children: [run(h, { bold: true, size: 18, color: WHITE })]
      })]
    })
  ));

  const dataRows = rows.map((r, ri) =>
    trow(r.map((val, ci) =>
      new TableCell({
        shading: { fill: ri % 2 === 0 ? WHITE : LIGHT, type: ShadingType.CLEAR, color: "auto" },
        width: { size: widths[ci], type: WidthType.DXA },
        verticalAlign: VerticalAlign.CENTER,
        margins: { top: 60, bottom: 60, left: 100, right: 100 },
        children: [new Paragraph({
          alignment: ci === 0 ? AlignmentType.CENTER : AlignmentType.LEFT,
          spacing: { before: 0, after: 0 },
          children: [run(val, {
            size: 18,
            bold: ci === 0 || (ci === 3 && (val === "LIFE-THREATENING" || val === "MAJOR")),
            color: ci === 3 ? (val === "LIFE-THREATENING" ? RED : val === "MAJOR" ? "B45309" : BLACK) : BLACK
          })]
        })]
      })
    ))
  );

  return new Table({ width: { size: 9026, type: WidthType.DXA }, rows: [headerRow, ...dataRows] });
};

// ═══════════════════════════════════════════════════════════════════════════════
// BUILD CASE BLOCKS
// ═══════════════════════════════════════════════════════════════════════════════

function buildCase(n, caseData) {
  const blocks = [];
  blocks.push(caseTitle(n, caseData.title));
  blocks.push(patientTable(caseData.patient));
  blocks.push(new Paragraph({ spacing: { before: 80, after: 0 }, children: [run("")] }));

  blocks.push(sectionLabel("Reason for Admission / Visit C/O"));
  blocks.push(textBlock(caseData.reason));

  blocks.push(sectionLabel("Drug Related Problem(s) Identified"));
  blocks.push(new Paragraph({ spacing: { before: 40, after: 20 }, children: [
    run("Drug Pair: ", { bold: true, size: 21, color: RED }),
    run(caseData.drugPair, { bold: true, size: 21, color: RED })
  ]}));
  blocks.push(textBlock(caseData.problem));

  blocks.push(sectionLabel("Reason(s) for Intervention"));
  caseData.reasons.forEach((r, i) => blocks.push(suggLine(i + 1, r)));

  blocks.push(sectionLabel("Suggestions Made"));
  caseData.suggestions.forEach((s, i) => blocks.push(suggLine(i + 1, s)));

  blocks.push(new Paragraph({ spacing: { before: 100, after: 40 }, children: [run("")] }));
  blocks.push(sigTable(caseData.hcp, "Pharm. Arjun Hegde", "Dr. Noorjahan, Dept. of Clinical Pharmacy", "YES", "YES"));
  blocks.push(hrule());
  return blocks;
}

// ═══════════════════════════════════════════════════════════════════════════════
// CASE DATA
// ═══════════════════════════════════════════════════════════════════════════════
const cases = [
  {
    title: "Warfarin + Aspirin",
    patient: { name: "Ramesh Kumar", age: "62 yrs", doa: "13/07/2026", ipop: "IP/2026/001",
      weight: "72 kg", gender: "Male", intDate: "13/07/2026", unit: "Cardiology Ward" },
    reason: "Patient admitted with chest pain, palpitations, and shortness of breath. Diagnosed with Atrial Fibrillation (AF) and Ischemic Heart Disease. Currently on long-term anticoagulation therapy with warfarin. Aspirin 300 mg was co-prescribed by a different physician for its antiplatelet effect.",
    drugPair: "Warfarin + Aspirin (300 mg)",
    problem: "Both drugs were prescribed concurrently producing a major pharmacodynamic interaction. Warfarin is a Vitamin K antagonist and Aspirin irreversibly inhibits platelet COX-1, blocking thromboxane A2-mediated platelet aggregation. Together they produce additive/synergistic anticoagulation with significantly increased bleeding risk. Aspirin also irritates the gastric mucosa, compounding hemorrhagic risk. INR on admission: 4.2 (therapeutic range 2.0-3.0). Patient reported melena (black tarry stools) indicating upper GI bleeding.",
    reasons: [
      "INR supratherapeutic at 4.2 - above therapeutic range of 2.0-3.0",
      "Concurrent antiplatelet + anticoagulant prescribed without gastroprotective cover",
      "Melena indicating active upper GI bleed",
      "No prior documentation of intentional dual therapy (e.g., mechanical heart valve indication)",
      "Patient had not been counseled on bleeding risk signs"
    ],
    suggestions: [
      "Temporarily hold warfarin dose and recheck INR after 48 hours",
      "Add Pantoprazole 40 mg OD as gastroprotective therapy",
      "Evaluate necessity of dual therapy (warfarin + aspirin) for this patient's specific indication",
      "If dual therapy is truly essential (e.g., AF + recent ACS), reduce aspirin to lowest effective dose (75 mg)",
      "Counsel patient on signs of bleeding: unusual bruising, blood in urine, black stools",
      "Dietary counseling on Vitamin K-containing foods affecting INR",
      "Regular INR monitoring every 2 weeks once stable"
    ],
    hcp: "Dr. Suresh Naik, Cardiologist"
  },
  {
    title: "Ciprofloxacin + Metformin",
    patient: { name: "Sunita Devi", age: "55 yrs", doa: "13/07/2026", ipop: "IP/2026/002",
      weight: "65 kg", gender: "Female", intDate: "13/07/2026", unit: "General Medicine" },
    reason: "Patient with known Type 2 Diabetes Mellitus on Metformin 1000 mg BD admitted with urinary tract infection (UTI). Ciprofloxacin 500 mg BD prescribed by the treating physician. Hypoglycemia episode (BG: 58 mg/dL) noted on Day 1.",
    drugPair: "Ciprofloxacin (Fluoroquinolone) + Metformin (Biguanide)",
    problem: "Ciprofloxacin inhibits organic cation transporter 2 (OCT2) in the renal tubules - the primary secretory elimination pathway for metformin. This inhibition reduces metformin renal clearance, increasing plasma levels and risk of lactic acidosis. Fluoroquinolones independently cause dysglycemia (both hypoglycemia and hyperglycemia). Patient eGFR borderline at 52 mL/min/1.73m2 further reducing metformin clearance. Blood glucose on admission: 58 mg/dL. Lactic acidosis is rare but potentially fatal.",
    reasons: [
      "Hypoglycemia episode (BG 58 mg/dL) on Day 1 of combined therapy",
      "Metformin dose not adjusted despite new fluoroquinolone prescription",
      "Borderline eGFR (52 mL/min/1.73m2) already compromising metformin renal clearance",
      "No monitoring plan documented for renal function or blood glucose during antibiotic course"
    ],
    suggestions: [
      "Reduce Metformin dose to 500 mg BD during the antibiotic course",
      "Monitor blood glucose every 4 hours during treatment",
      "Monitor serum creatinine and eGFR every 48 hours",
      "Consider switching antibiotic to Nitrofurantoin or Co-trimoxazole for uncomplicated UTI (less interaction risk)",
      "Counsel patient to report muscle pain, weakness, or difficulty breathing (lactic acidosis symptoms)",
      "Resume standard metformin dose only after completing antibiotics and confirming stable renal function"
    ],
    hcp: "Dr. Meera Krishnamurthy, General Physician"
  },
  {
    title: "Phenytoin + Amlodipine",
    patient: { name: "Ajay Sharma", age: "48 yrs", doa: "13/07/2026", ipop: "OP/2026/003",
      weight: "80 kg", gender: "Male", intDate: "13/07/2026", unit: "Neurology OPD" },
    reason: "Patient with longstanding epilepsy on Phenytoin 300 mg OD presenting for review. Diagnosed with essential hypertension 3 months ago and started on Amlodipine 10 mg OD (maximum dose). BP remains poorly controlled at 156/98 mmHg despite 3 months of therapy.",
    drugPair: "Phenytoin (Antiepileptic) + Amlodipine (CCB)",
    problem: "Phenytoin is a potent inducer of hepatic CYP3A4. Amlodipine, a dihydropyridine calcium channel blocker, is primarily metabolized by CYP3A4. Phenytoin dramatically accelerates amlodipine metabolism, reducing plasma amlodipine concentrations by up to 80-90%. This results in subtherapeutic amlodipine levels and loss of antihypertensive effect, explaining persistent poor BP control despite maximum dosing. Further increasing amlodipine beyond 10 mg is not clinically feasible.",
    reasons: [
      "BP inadequately controlled (156/98 mmHg) on maximum dose amlodipine (10 mg OD) for 3 months",
      "Pharmacokinetic drug interaction with phenytoin (CYP3A4 inducer) identified as likely cause",
      "Further increasing amlodipine dose not recommended and would be ineffective",
      "Risk of hypertensive stroke or cardiac event if unaddressed"
    ],
    suggestions: [
      "Discontinue Amlodipine - ineffective in the presence of a strong CYP3A4 inducer",
      "Switch to Atenolol 50 mg OD (beta-blocker, not a CYP3A4 substrate - safe alternative)",
      "Alternatively consider Losartan (ARB) - minimal CYP3A4 involvement",
      "Add Chlorthalidone (thiazide-like diuretic) if BP control remains inadequate on monotherapy",
      "Recheck BP in 4 weeks after switching antihypertensive",
      "Therapeutic drug monitoring (TDM) of phenytoin levels to ensure anti-epileptic efficacy",
      "Do NOT abruptly stop phenytoin - risk of breakthrough seizures"
    ],
    hcp: "Dr. Praveen Kamath, Neurologist"
  },
  {
    title: "Fluoxetine (SSRI) + Sumatriptan (Triptan)",
    patient: { name: "Fatima Begum", age: "60 yrs", doa: "13/07/2026", ipop: "IP/2026/004",
      weight: "58 kg", gender: "Female", intDate: "13/07/2026", unit: "Psychiatry" },
    reason: "Patient with chronic Major Depressive Disorder on Fluoxetine 40 mg OD for 18 months. Referred to neurology for newly diagnosed migraine; Sumatriptan 50 mg PRN prescribed. Patient reported palpitations and mild restlessness after first sumatriptan dose.",
    drugPair: "Fluoxetine (SSRI) + Sumatriptan (5-HT1B/1D Agonist)",
    problem: "Fluoxetine blocks SERT (serotonin reuptake transporter), increasing synaptic serotonin. Sumatriptan is a direct 5-HT1B/1D receptor agonist. Combined serotonergic activity - presynaptic accumulation (SSRI) plus direct receptor agonism (triptan) - can precipitate Serotonin Syndrome. Classic triad: (1) Altered mental status/agitation, (2) Autonomic instability (tachycardia, hyperthermia, diaphoresis), (3) Neuromuscular abnormalities (tremor, hyperreflexia, clonus). Patient already experiencing early symptoms after first dose.",
    reasons: [
      "High-risk serotonin syndrome combination prescribed without interdepartmental communication",
      "Patient already experiencing palpitations and restlessness after first sumatriptan dose - early serotonin syndrome signs",
      "Both prescribers unaware of each other's prescriptions (polypharmacy from multiple departments)",
      "60-year-old female - higher vulnerability to adverse drug reactions"
    ],
    suggestions: [
      "Discontinue Sumatriptan immediately",
      "For acute migraine: switch to NSAIDs (Naproxen 500 mg), antiemetics (Metoclopramide), or Paracetamol 1 g",
      "If triptan is clinically essential, consider low-dose Naratriptan or Frovatriptan under close monitoring",
      "Educate patient on serotonin syndrome warning signs: fever, agitation, shivering, diarrhea, muscle twitching",
      "Implement formal medication reconciliation between psychiatry and neurology departments",
      "Consider non-pharmacological migraine management: trigger avoidance, relaxation techniques, biofeedback"
    ],
    hcp: "Dr. Anand Reddy, Psychiatrist"
  },
  {
    title: "ACE Inhibitor (Enalapril) + NSAID (Indomethacin)",
    patient: { name: "Venkatesh Rao", age: "70 yrs", doa: "13/07/2026", ipop: "IP/2026/005",
      weight: "75 kg", gender: "Male", intDate: "13/07/2026", unit: "Nephrology" },
    reason: "Chronic Kidney Disease Stage 3 (eGFR: 38 mL/min/1.73m2) with hypertension managed on Enalapril 10 mg OD. Admitted with acute gout flare; Indomethacin 50 mg TDS prescribed for 5 days. Serum creatinine rose from 1.6 to 2.4 mg/dL within 48 hours.",
    drugPair: "Enalapril (ACE Inhibitor) + Indomethacin (NSAID)",
    problem: "This is the classic 'triple whammy' interaction. (1) NSAIDs inhibit prostaglandin (PGE2, PGI2) synthesis - these normally dilate the afferent arteriole maintaining GFR. Inhibition causes afferent constriction and reduced filtration. (2) ACE inhibitors block angiotensin II-mediated efferent arteriolar constriction that compensates for reduced afferent flow. Together both drugs unmask hemodynamic renal vulnerability, causing AKI superimposed on CKD. Serum creatinine rose from 1.6 to 2.4 mg/dL in 48 hours. Urine output dropped to 600 mL/day.",
    reasons: [
      "Rapidly rising creatinine (1.6 to 2.4 mg/dL in 48 hrs) - AKI on CKD",
      "Reduced urine output (600 mL/day) indicating impaired renal perfusion",
      "Patient has CKD-3 - vulnerable baseline already compromised",
      "NSAIDs contraindicated or strongly cautioned in CKD + ACE inhibitor combination"
    ],
    suggestions: [
      "Immediately discontinue Indomethacin",
      "Manage acute gout with Colchicine 0.5 mg BD (renal dose-adjusted) as first alternative",
      "If colchicine not tolerated, use short-course oral Prednisolone 20-30 mg OD",
      "Ensure adequate hydration (IV fluids if oral intake insufficient)",
      "Monitor serum creatinine, urea, and electrolytes daily until renal function stabilizes",
      "Monitor serum potassium closely - ACE inhibitor + renal impairment risks hyperkalemia",
      "Reduce Enalapril dose if eGFR falls below 30 mL/min/1.73m2"
    ],
    hcp: "Dr. Rajesh Shetty, Nephrologist"
  },
  {
    title: "Rifampicin + Oral Contraceptive Pill (OCP)",
    patient: { name: "Priya Nair", age: "35 yrs", doa: "13/07/2026", ipop: "OP/2026/006",
      weight: "54 kg", gender: "Female", intDate: "13/07/2026", unit: "OB-GYN / Pulmonology" },
    reason: "Young female on Combined OCP (Ethinylestradiol + Levonorgestrel) for contraception. Newly diagnosed with Pulmonary Tuberculosis (PTB) and initiated on RIPE regimen (Rifampicin 600 mg OD, Isoniazid, Pyrazinamide, Ethambutol). Patient not counseled about contraceptive failure risk.",
    drugPair: "Rifampicin (Anti-TB) + Combined OCP (Ethinylestradiol + Levonorgestrel)",
    problem: "Rifampicin is one of the most potent inducers of hepatic CYP3A4, CYP2C9, and P-glycoprotein (P-gp). Ethinylestradiol and levonorgestrel in OCPs are primarily CYP3A4 substrates. Rifampicin dramatically accelerates their hepatic metabolism, reducing estrogen and progestogen plasma levels by 40-80%. This renders hormonal contraception clinically INEFFECTIVE. P-gp induction further reduces OCP absorption from the GI tract. Enzyme induction persists for 4-8 weeks after stopping rifampicin. Unintended pregnancy during anti-TB treatment poses serious risk (drug teratogenicity concerns with Pyrazinamide and Ethambutol).",
    reasons: [
      "Patient not informed that OCP is no longer effective during rifampicin treatment",
      "Unintended pregnancy risk during anti-TB therapy with potential fetal drug exposure",
      "Patient's entire reproductive planning relies on a now-ineffective method",
      "Both prescribers unaware of this critical interaction"
    ],
    suggestions: [
      "Counsel patient clearly: OCP is NO LONGER EFFECTIVE as contraception during rifampicin treatment",
      "Immediately switch to a copper intrauterine device (Cu-IUD) - highly effective, non-hormonal, not affected by rifampicin",
      "Alternatively use consistent barrier method (condoms) throughout TB treatment",
      "If OCP is continued, must use dual contraception (OCP + barrier method) simultaneously",
      "Maintain non-hormonal contraception for at least 4-8 weeks after completing rifampicin",
      "Document counseling provided and obtain informed consent from patient",
      "Coordinate with OB-GYN department for IUD insertion if chosen"
    ],
    hcp: "Dr. Kavitha Bhat, Pulmonologist"
  },
  {
    title: "Digoxin + Furosemide (Hypokalemia-Mediated Toxicity)",
    patient: { name: "Suresh Patel", age: "65 yrs", doa: "13/07/2026", ipop: "IP/2026/007",
      weight: "82 kg", gender: "Male", intDate: "13/07/2026", unit: "Cardiology" },
    reason: "Chronic Heart Failure (NYHA Class III) on Digoxin 0.25 mg OD and Furosemide 80 mg OD. Presents with nausea, vomiting, yellow-green visual halos, and bradycardia (HR: 46 bpm). Serum K+: 2.8 mEq/L. Digoxin level: 3.2 ng/mL (therapeutic: 0.5-2.0 ng/mL).",
    drugPair: "Digoxin + Furosemide (via Furosemide-induced Hypokalemia)",
    problem: "Furosemide, a loop diuretic, inhibits the Na-K-2Cl cotransporter in the thick ascending limb of Henle's loop, causing renal potassium wasting and hypokalemia (K+ 2.8 mEq/L). Digoxin inhibits Na+/K+-ATPase on cardiac myocytes. Hypokalemia also inhibits Na+/K+-ATPase (K+ is the natural activating substrate), creating synergistic inhibition. This leads to dangerous intracellular calcium accumulation via the Na+/Ca2+ exchanger, producing bradycardia, AV block, and potentially lethal ventricular arrhythmias. Classic digoxin toxicity confirmed: level 3.2 ng/mL + visual disturbances + bradycardia (HR 46).",
    reasons: [
      "Digoxin toxicity confirmed: level 3.2 ng/mL (supratherapeutic) with clinical symptoms",
      "Furosemide-induced hypokalemia (K+ 2.8 mEq/L) synergistically potentiating toxicity",
      "Patient not on potassium supplementation despite long-term furosemide use",
      "Bradycardia (HR 46 bpm) indicating risk of complete heart block or cardiac arrest"
    ],
    suggestions: [
      "URGENT: Hold Digoxin immediately pending level normalization",
      "Administer IV Potassium Chloride (KCl) 40 mEq in 500 mL NS over 4 hours under continuous ECG monitoring",
      "Maintain continuous cardiac monitoring; watch for AV block, VT, or VF",
      "If life-threatening arrhythmia occurs, administer Digoxin-specific Fab antibody fragments (Digibind/DigiFab)",
      "Add Spironolactone 25 mg OD (potassium-sparing diuretic) to prevent recurrent furosemide-induced hypokalemia",
      "Reduce Furosemide to minimum effective dose for symptom control",
      "Once stable, restart Digoxin at reduced dose (0.125 mg OD) with strict therapeutic drug monitoring"
    ],
    hcp: "Dr. Suresh Naik, Cardiologist"
  },
  {
    title: "Levothyroxine + Ferrous Sulfate",
    patient: { name: "Rekha Iyer", age: "45 yrs", doa: "13/07/2026", ipop: "OP/2026/008",
      weight: "61 kg", gender: "Female", intDate: "13/07/2026", unit: "Endocrinology OPD" },
    reason: "Primary hypothyroidism on Levothyroxine 150 mcg OD for review. TSH persistently elevated at 8.4 mIU/L (normal: 0.4-4.0) despite 6 months of therapy and two dose increments. Concurrent iron-deficiency anemia on Ferrous Sulfate 200 mg TDS. Patient takes both medications simultaneously every morning.",
    drugPair: "Levothyroxine (T4) + Ferrous Sulfate (Iron Supplement)",
    problem: "Ferrous sulfate (Fe2+) forms an insoluble chelate complex with levothyroxine in the GI tract when administered simultaneously. This physicochemical interaction significantly impairs intestinal absorption of levothyroxine, reducing its bioavailability by 30-80% (studies show AUC reduction up to 80%). Reduced absorption leads to persistently subtherapeutic levothyroxine plasma levels and inadequate TSH suppression. Similar interactions occur with other divalent cations: calcium carbonate, aluminum/magnesium antacids, sucralfate. Patient has been on unnecessarily escalated doses because the root interaction was not identified for 6 months.",
    reasons: [
      "Persistently elevated TSH (8.4 mIU/L) despite adequate levothyroxine dose and two prior dose increments",
      "Patient taking both tablets simultaneously every morning - root cause of treatment failure identified",
      "Patient symptomatic with fatigue, cold intolerance, and weight gain - uncontrolled hypothyroidism",
      "Drug interaction not documented by any prior prescriber despite 6 months of concurrent prescription"
    ],
    suggestions: [
      "Instruct patient to take Levothyroxine FIRST upon waking, 30-60 minutes before breakfast, with plain water ONLY",
      "Take Ferrous Sulfate at a separate time - minimum 4 hours after levothyroxine (e.g., with lunch or dinner)",
      "Do NOT co-administer levothyroxine with calcium, antacids, dairy products, or coffee",
      "Reassess the previously increased levothyroxine dose - may now be excessive once absorption normalizes",
      "Recheck TSH and Free T4 in 6 weeks after correcting administration timing",
      "Titrate levothyroxine dose downward if TSH becomes suppressed after interaction is resolved",
      "Provide a written instruction card on correct timing and pin to medication packaging"
    ],
    hcp: "Dr. Girish Rao, Endocrinologist"
  },
  {
    title: "Theophylline + Clarithromycin",
    patient: { name: "Mohammed Irfan", age: "52 yrs", doa: "13/07/2026", ipop: "IP/2026/009",
      weight: "78 kg", gender: "Male", intDate: "13/07/2026", unit: "Pulmonology" },
    reason: "COPD (GOLD Stage III) on Theophylline SR 400 mg BD. Clarithromycin 500 mg BD prescribed by GP for community-acquired pneumonia. Now presenting with nausea, vomiting, tachycardia (HR: 122 bpm), and tremors. Serum theophylline level: 28 mcg/mL (toxic; therapeutic range: 10-20 mcg/mL).",
    drugPair: "Theophylline (Xanthine Bronchodilator, NTI Drug) + Clarithromycin (Macrolide Antibiotic)",
    problem: "Theophylline has a narrow therapeutic index (NTI); therapeutic range 10-20 mcg/mL, toxic >20 mcg/mL. It is primarily metabolized by hepatic CYP1A2 and CYP3A4. Clarithromycin is a potent inhibitor of CYP3A4 (and partial CYP1A2 inhibitor). When clarithromycin inhibits these enzymes, theophylline clearance is significantly reduced, causing accumulation to toxic levels (28 mcg/mL). Theophylline toxicity: GI (nausea, vomiting), cardiovascular (tachycardia, arrhythmias), neurological (tremors, seizures, agitation). Drug prescribed by GP without checking existing medication profile. Other drugs with similar interaction: erythromycin, ciprofloxacin, enoxacin, cimetidine.",
    reasons: [
      "Clinical theophylline toxicity confirmed: level 28 mcg/mL with tachycardia (HR 122), tremors, and vomiting",
      "Clarithromycin prescribed by GP without reviewing existing medication profile",
      "Theophylline dose not adjusted despite addition of a known CYP3A4 inhibitor",
      "Narrow therapeutic index drug with serious and potentially life-threatening toxicity"
    ],
    suggestions: [
      "URGENT: Withhold Theophylline immediately; check serum theophylline STAT",
      "Discontinue Clarithromycin; substitute with Doxycycline 100 mg BD or Amoxicillin-Clavulanate (no significant CYP3A4 effect on theophylline)",
      "Symptomatic management: IV fluids for hydration; Propranolol (cautiously) for severe tachycardia if no contraindication",
      "Continuous cardiac monitoring (ECG) until theophylline level falls within therapeutic range",
      "Once symptoms resolve and levels normalize, restart theophylline at 75% of previous dose",
      "If clarithromycin cannot be substituted, reduce theophylline dose by 50% and monitor levels every 48 hours",
      "Patient education: Never take new medications (including OTC) without informing the pharmacist due to NTI drug status"
    ],
    hcp: "Dr. Kavitha Bhat, Pulmonologist"
  },
  {
    title: "Alendronate + Calcium Carbonate",
    patient: { name: "Lakshmi Bai", age: "68 yrs", doa: "13/07/2026", ipop: "OP/2026/010",
      weight: "63 kg", gender: "Female", intDate: "13/07/2026", unit: "Orthopedics OPD" },
    reason: "Post-menopausal woman with established osteoporosis on Alendronate 70 mg once weekly and Calcium Carbonate 1250 mg + Vitamin D3 500 IU BD for 18 months. DEXA scan shows worsening osteoporosis (T-score: -3.2). Patient takes all medications together in the morning before breakfast.",
    drugPair: "Alendronate (Bisphosphonate) + Calcium Carbonate (Divalent Cation Supplement)",
    problem: "Bisphosphonates have inherently poor oral bioavailability (approx. 1-5% under optimal fasting conditions). This drops dramatically when taken with calcium supplements, dairy, or any polyvalent cation. Calcium ions (Ca2+) chelate directly with the bisphosphonate molecule in the GI lumen, forming an insoluble, unabsorbable calcium-alendronate complex. Studies show co-administration reduces alendronate bioavailability by over 60%. With insufficient systemic alendronate, osteoclast activity is not inhibited, bone resorption continues, and osteoporosis worsens - exactly what is seen with the deteriorating T-score (-3.2) after 18 months of apparently adequate therapy.",
    reasons: [
      "Worsening DEXA BMD (T-score -3.2) after 18 months of alendronate - apparent treatment failure",
      "Interaction identified as root cause: patient taking alendronate simultaneously with calcium carbonate",
      "Continued bone loss significantly increases vertebral and hip fracture risk in this patient",
      "No pharmacist counseling previously documented on correct alendronate administration technique"
    ],
    suggestions: [
      "Instruct patient: Alendronate must be taken on an EMPTY STOMACH upon waking with a FULL glass (250 mL) of plain water ONLY",
      "Patient must remain UPRIGHT (sitting or standing) for at least 30 minutes post-dose to prevent esophageal ulceration",
      "Must NOT eat, drink (except plain water), or take any other medication for 30-60 minutes after alendronate",
      "Take Calcium Carbonate + Vitamin D3 at a SEPARATE time (minimum 2 hours later, ideally with lunch or dinner)",
      "Recheck DEXA bone mineral density in 12 months after correcting administration - expect measurable improvement",
      "Assess modifiable osteoporosis risk factors: smoking, alcohol, physical activity level, fall prevention measures",
      "Provide written instruction card for correct alendronate administration technique attached to packaging"
    ],
    hcp: "Dr. Mahesh Shenoy, Orthopedic Surgeon"
  }
];

// ═══════════════════════════════════════════════════════════════════════════════
// ASSEMBLE DOCUMENT
// ═══════════════════════════════════════════════════════════════════════════════

const headerPara = (text, opts = {}) =>
  new Paragraph({
    alignment: opts.center ? AlignmentType.CENTER : AlignmentType.LEFT,
    spacing: { before: opts.before || 0, after: opts.after || 0 },
    children: [run(text, opts)]
  });

const children = [];

// ── Cover / Title Block ──────────────────────────────────────────────────────
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 200, after: 40 },
  shading: { fill: NAVY, type: ShadingType.CLEAR, color: "auto" },
  children: [run("RIFA-HUL MUSLIMEEN EDUCATIONAL TRUST (REGD.)", { bold: true, size: 18, color: WHITE })]
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 0 },
  shading: { fill: NAVY, type: ShadingType.CLEAR, color: "auto" },
  children: [run("FAROOQIA COLLEGE OF PHARMACY", { bold: true, size: 36, color: WHITE })]
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 0 },
  shading: { fill: NAVY, type: ShadingType.CLEAR, color: "auto" },
  children: [run("DEPARTMENT OF CLINICAL PHARMACY", { bold: true, size: 22, color: LIGHT })]
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 20 },
  shading: { fill: NAVY, type: ShadingType.CLEAR, color: "auto" },
  children: [run("Farooqia Road, Eidgah, Mysore - 570 021, Karnataka, India", { size: 17, color: LIGHT })]
}));

children.push(new Paragraph({ spacing: { before: 60, after: 60 }, children: [run("")] }));

children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 60, after: 20 },
  shading: { fill: TEAL, type: ShadingType.CLEAR, color: "auto" },
  children: [run("PHARMACIST INTERVENTION REPORTING & DOCUMENTATION FORM", { bold: true, size: 28, color: WHITE })]
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 10, after: 20 },
  shading: { fill: TEAL, type: ShadingType.CLEAR, color: "auto" },
  children: [run("10 Clinically Significant Drug Interactions - Training Reference Document", { size: 22, color: WHITE, italics: true })]
}));

children.push(new Paragraph({ spacing: { before: 60, after: 40 }, children: [run("")] }));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 60 },
  children: [run("Date: 13 July 2026  |  Prepared by: Dept. of Clinical Pharmacy, Farooqia College of Pharmacy", { size: 19, italics: true, color: "555555" })]
}));

children.push(hrule());
children.push(new Paragraph({ spacing: { before: 60, after: 60 }, children: [run("")] }));

// ── Quick Reference Summary Table ────────────────────────────────────────────
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 80, after: 60 },
  shading: { fill: NAVY, type: ShadingType.CLEAR, color: "auto" },
  children: [run("QUICK REFERENCE SUMMARY - ALL 10 DRUG INTERACTIONS", { bold: true, size: 24, color: WHITE })]
}));
children.push(summaryTable());
children.push(new Paragraph({ spacing: { before: 60, after: 60 }, children: [run("")] }));

// ── Page break before cases ──────────────────────────────────────────────────
children.push(pageBreak());

// ── All 10 case blocks ───────────────────────────────────────────────────────
cases.forEach((c, i) => {
  const blocks = buildCase(i + 1, c);
  blocks.forEach(b => children.push(b));
  if (i < cases.length - 1) {
    children.push(new Paragraph({ spacing: { before: 60, after: 60 }, children: [run("")] }));
    children.push(pageBreak());
  }
});

// ═══════════════════════════════════════════════════════════════════════════════
// BUILD & WRITE
// ═══════════════════════════════════════════════════════════════════════════════
const doc = new Document({
  numbering: {
    config: [
      { reference: "bullets",
        levels: [{ level: 0, format: LevelFormat.BULLET, text: "-", alignment: AlignmentType.LEFT,
          style: { paragraph: { indent: { left: 360, hanging: 180 } } } }] }
    ]
  },
  styles: {
    default: { document: { run: { font: "Arial", size: 22 } } },
  },
  sections: [{
    properties: {
      page: {
        margin: { top: 720, bottom: 720, left: 900, right: 900 },
        size: { width: 11906, height: 16838 }
      }
    },
    headers: {
      default: new Header({
        children: [new Paragraph({
          alignment: AlignmentType.CENTER,
          border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
          spacing: { before: 0, after: 60 },
          children: [
            run("Farooqia College of Pharmacy | Dept. of Clinical Pharmacy | Drug Interactions Training Reference", { size: 17, color: TEAL, italics: true })
          ]
        })]
      })
    },
    footers: {
      default: new Footer({
        children: [new Paragraph({
          alignment: AlignmentType.CENTER,
          border: { top: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
          spacing: { before: 60, after: 0 },
          children: [
            run("Page ", { size: 17, color: "555555" }),
            new PageNumber ? run("", { size: 17 }) : run("", {}),
          ]
        })]
      })
    },
    children
  }]
});

Packer.toBuffer(doc).then(buf => {
  fs.writeFileSync("/home/daytona/workspace/drug-interactions/Drug_Interactions_Training_Reference.docx", buf);
  console.log("SUCCESS: Document created.");
});

Running Command

cd /home/daytona/workspace/drug-interactions && node generate.js 2>&1

Editing File

~/drug-interactions/generate.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/drug-interactions/generate.js'

Running Command

cd /home/daytona/workspace/drug-interactions && node generate.js 2>&1

Running Command

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…

Running Command

ls -lh /home/daytona/workspace/drug-interactions/Drug_Interactions_Training_Refe…

Your Word document is ready for download:

Drug Interactions Training Reference

Word Document · DOCX

What's inside the document:

Cover Page / Title Block

Full Farooqia College of Pharmacy header (navy background, white text) matching the original form
Title: "Pharmacist Intervention Reporting & Documentation Form - 10 Drug Interactions Training Reference"

Quick Reference Summary Table (at the start)

All 10 cases in a colour-coded table: drug pair, mechanism, severity (red for Life-Threatening, amber for Major), clinical risk, and key action - great for at-a-glance review

10 Full Case Reports (one per page), each containing:

Patient info table (name, age, IP/OP no., weight, gender, unit, dates)
Reason for Admission/Visit
Drug Related Problem(s) Identified - with drug pair in red, full mechanism explanation
Reason(s) for Intervention - numbered list
Suggestions Made - detailed numbered recommendations
Signature block (HCP, Pharmacist, Preceptor with Yes/No fields)

Colour scheme mirrors the form's academic style:

Navy headers, teal section labels, light-blue shading for info rows, red for Major/Life-threatening severity

This is a shared conversation. Sign in to Orris to start your own chat.